Systematic review, meta-analysis and economic modelling of ...

More documents

Recommendations

Info

Assessment of cost-effectiveness evidenceTABLE 52 Cost-effectiveness of adding alternative biomarkers to troponinStudyBiomarkersPresentation troponinalone (£/QALY)Presentation troponinand biomarker (£/QALY)10-hour troponintesting (£/QALY)Body 2011 57 TnI or H-FABP 6596 5120 24,147Haltern TnT or H-FABP 4849 14,615 58,3302010 67McCann TnT or H-FABP 5296 5945 54,8202008 76Mion 2007 77 TnI or H-FABP 5785 6125 18,904Keller 2010 71TnT orcopeptin5545 9606 23,222Reichlin TnT or2009 80 copeptin5295 9244 117,176Keller 2010 71Mion 2007 77TnT ormyoglobinTnI ormyoglobin5545 7769 22,7335785 5877 23,048Collinson TnT or IMA 4874 99,948 Dominated2006 48Keating TnT or IMA 4876 Extendedly dominated 23,6582006 70Probabilistic results of the diagnostic modelProbabilistic analysis incorporated uncertainty in the parameter estimates to provide estimates of theprobability that each strategy would be cost-effective at different thresholds for willingness to pay forhealth gain. Figures 38–40 show the probabilistic analysis for patients without known CAD accordingto the doctor-on-demand, twice-daily ward and once-daily ward scenarios. The tables containing theprobabilities at different willingness-to-pay thresholds are in Appendix 7. The probabilistic results weresimilar to those of the deterministic analysis, with the conclusions identical for both methodologies.These analyses show that the strategy based on measuring high-sensitivity troponin at presentation hadthe highest probability of being cost-effective for thresholds of between around £5000 and £23,000/QALYin the doctor-on-demand strategy and for thresholds exceeding around £10,000/QALY for the other twostrategies. For thresholds exceeding around £23,000/QALY in the doctor-on-demand scenario the 10-hourtroponin strategy had the highest probability of being cost-effective. These results reflect the deterministicanalysis and suggest that high-sensitivity troponin on presentation has the highest probability of beingcost-effective in most scenarios and at typically used thresholds for willingness to pay.The prognostic phase modelThis section details the methods and results of the health economic model constructed to compareprognostic strategies for troponin-negative patients without known CAD. We developed a decision-analyticmodel to estimate the costs and QALYs accrued by each potential management strategy for identifyingpatients with subsequent risk of MACEs. The strategies involved using CTCA, exercise ECG or a biomarker(H-FABP) to select patients for further investigation with ICA. We also included a ‘perfect’ strategy of ICAfor all patients and a no-testing strategy. We assumed that patients who were discharged without testingwould ultimately present with further symptoms and receive appropriate testing if they did not die in themeantime. The key aim was to determine the optimal strategy in terms of cost-effectiveness.96NIHR Journals Library
DOI: 10.3310/hta17010 Health Technology Assessment 2013 Vol. 17 No. 11.0Probability of cost-effectiveness0.80.60.40.200 10 203040 50No testing10% CV99th percentileHigh-sensitivitytroponin10-hour troponin–0.2Willingness-to-pay threshold (£000)FIGURE 38 Probability of cost-effectiveness of strategies in doctor-on-demand scenario.1.0Probability of cost-effectiveness0.80.60.40.200 10 203040 50No testing10% CV99th percentileHigh-sensitivitytroponin10-hour troponin–0.2Willingness-to-pay threshold (£000)FIGURE 39 Probability of cost-effectiveness of strategies in twice-daily ward scenario.1.0Probability of cost-effectiveness0.80.60.40.200 10 203040 50No testing10% CV99th percentileHigh-sensitivitytroponin10-hour troponin–0.2Willingness-to-pay threshold (£000)FIGURE 40 Probability of cost-effectiveness of strategies in once-daily ward scenario.© Queen’s Printer and Controller of HMSO 2013. This work was produced by Goodacre et al. under the terms of a commissioning contract issued by the Secretary of Statefor Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journalsprovided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should beaddressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton SciencePark, Southampton SO16 7NS, UK.97
Page 1:
Health Technology AssessmentVOLUME
Page 7:
DOI: 10.3310/hta17010 Health Techno
Page 10 and 11:
ContentsAppendix 5 Expected discoun
Page 13 and 14:
Page 15 and 16:
Page 17 and 18:
Page 19:
Page 22 and 23:
BackgroundTABLE 1 Hospital admissio
Page 24 and 25:
Background2. investigation of the c
Page 26 and 27:
BackgroundComputed tomographic coro
Page 28 and 29:
Research questionsiii. the diagnost
Page 30 and 31:
Assessment of diagnostic and progno
Page 32 and 33:
Page 34 and 35:
Page 36 and 37:
Page 38 and 39:
Page 40 and 41:
Page 42 and 43:
Page 44 and 45:
Page 46 and 47:
Page 48 and 49:
Page 50 and 51:
Page 52 and 53:
Page 54 and 55:
Page 56 and 57:
Page 58 and 59:
Page 60 and 61:
Page 62 and 63:
Page 64 and 65:
Page 66 and 67: Assessment of diagnostic and progno
Page 91 and 92: DOI: 10.3310/hta17010 Health Techno
Page 115: DOI: 10.3310/hta17010 Health Techno
Page 128 and 129: Discussionspecificity were 62% (95%
Page 130 and 131: Discussionneed for revascularisatio
Page 132 and 133: Discussionchanges in sensitivity an
Page 134 and 135: Discussionuncertainty about these p
Page 136 and 137: Discussiontroponin assays have bett
Page 138 and 139: ConclusionsSuggested research prior
Page 154 and 155: Appendix 144. heart-type fatty acid
Page 156 and 157: Appendix 1135. interleukin 33.mp. (
Page 158 and 159: Appendix 147. 37 and 45 (529)48. li
Page 164 and 165: Appendix 313. Fernandez Portales JG
Page 166 and 167:
Appendix 346. Luscher MS, Ravkilde
Page 168 and 169:
Appendix 316. Rao SV, Ohman EM, Gra
Page 171 and 172:
Page 173 and 174:
Page 175 and 176:
Page 177 and 178:
Page 179 and 180:
Page 181 and 182:
Page 183:
Page 187 and 188:
Page 189 and 190:
Page 191 and 192:
Page 193 and 194:
Page 195:
Page 198 and 199:
Appendix 9Clinical diagnosis of NST
Page 200 and 201:
Appendix 9respectively. Exercise EC
Page 202 and 203:
Appendix 93. Two reviewers will mak
Page 204 and 205:
Appendix 9The methodology used in t
Page 206 and 207:
Appendix 9ES (Information Resources
Page 208:
Appendix 923. Westwood ME, Whiting
show all

Systematic review, meta-analysis and economic modelling of ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?